SNMX $0.83 +5% > Financial Results: >>
MY NEXT EBIO BCRX KBIO SOME 1000% BIO TECH TURN AROUND INVEST IMHO
Commercial revenues increased 24% to $2.8 million in the second quarter ended June 30, 2017. For the six months ended June 30, 2017, commercial revenues increased 25% to $5.5 million. These improvements primarily resulted from higher direct sales of flavor ingredients to flavor houses and higher royalties from sweet taste boosting ingredients
Senomyx ended the second quarter 2017 with no debt and $11.2 million in cash, an increase of $1.1 million during the second quarter. In addition, the Company is scheduled to receive $14.0 million in committed development funding in the future.
For the third quarter of 2017, the Company expects:
Revenues to be at least $4.7 million, of which at least $2.9 million are commercial revenues; and
Net loss not to exceed $3.2 million or $0.07 per share